資源 » 參考數據庫 » 客戶發表文獻

至今，GenScript的服務及產品已被Cell, Nature, Science, PNAS等1300多家生物醫藥類雜志引用近萬次，處于行業領先水平。NIH、哈佛、耶魯、斯坦福、普林斯頓、杜克大學等約400家全球著名機構使用GenScript的基因合成、多肽服務、抗體服務和蛋白服務等成功地發表科研成果，再次證明GenScript 有能力幫助業內科學家Make research easy.

Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients.

J Immunother Cancer. 2019-04;

SnookAdam E，BaybuttTrevor R，XiangBo，AbrahamTara S，FlickingerJohn C，HyslopTerry，ZhanTingting，KraftWalter K，SatoTakami，WaldmanSco

Products/Services Used	Details	Operation
Proteins, Expression, Isolation and Analysis	Hexahistidine-tagged human GUCY2CECD (amino acids 1– 429) protein was produced in suspension HEK293 cells and purified to > 90% purity by immobilized metal affinity chromatography (GenScript, Piscataway, NJ).	Get A Quote

摘要

The colorectal cancer antigen GUCY2C exhibits unique split tolerance， evoking antigen-specific CD8， but not CD4， T-cell responses that deliver anti-tumor immunity without autoimmunity in mice. Here， the cancer vaccine Ad5-GUCY2C-PADRE was evaluated in a first-in-man phase I clinical study of patients with early-stage colorectal cancer to assess its safety and immunological efficacy.